Comparing two types of stem cell transplants for children

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of TCRαβ depleted haploidentical stem cell transplantation compared to the traditional Beijing protocol in children requiring hematopoietic stem cell transplantation. It is a single-center, prospective, non-randomized controlled study conducted in China. The goal is to achieve a 30% reduction in the incidence of grade II-IV acute graft-versus-host disease (aGVHD) and to improve the quality of life for patients receiving the TCRαβ depleted cells.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 8 weeks to 18 years
* Children who meet the indicators haploidentical hematopoietic cell transplantation
* No HLA ≥ 9/10 donor or not suitable for this type of donor due to illness
* Informed consent must be signed (by the patient or legal representative)

Exclusion Criteria:

* Liver function abnormalities with bilirubin \>2 mg/dL and elevation of transaminases higher than 400 U/L
* Chronic active viral hepatitis
* Ejection fraction \<50%
* Respiratory failure necessitating supplemental oxygen
* Patients with a history of psychiatric illness or a condition which could interfere with their ability to understand the requirements of the study
* Patients unwilling or unable to comply with the protocol or unable to give informed consent
* Concurrent severe or uncontrolled infection

Where it's running

• Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Principal investigator: Jing Chen, PhD — Shanghai Children's Medical Center
• Study coordinator: Jing Chen, PhD
• Email: chenjing@scmc.com.cn
• Phone: 38626161

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using Ruxolitinib to prevent complications after haploidentical stem cell transplants

  This study is testing if the drug Ruxolitinib can help prevent complications like graft-versus-host disease in patients receiving stem cell transplants from partially matched donors.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT06008808

• Population PK-guided ATG Dosing in Haploidentical Stem Cell Transplant

  This trial tests a population PK-guided ATG dosing strategy in people undergoing haploidentical hematopoietic stem cell transplantation to see if it improves outcomes.

  Recruiting Phase 3 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07862127

• Population PK-guided ATG Dosing in Haplo-HSCT

  This study tests a population PK-guided dosing strategy for anti-thymocyte globulin (ATG) in adults and adolescents undergoing haploidentical stem cell transplantation to see if it can reduce GVHD while keeping relapse risk acceptable.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07791576

• Two Different Therapeutic Distractions Used During Blood Draw for Children Aged 5–7

  This study tests whether two distraction methods during blood sampling can reduce pain, fear, and anxiety in 5–7 year-olds compared with routine care.

  Recruiting Phase 1 Igdir University · Iğdır, Iğdır · NCT07731347

• Low-dose liposomal amphotericin B to prevent invasive fungal infections in neutropenic children

  This study tests whether giving a fixed low dose of liposomal amphotericin B can prevent invasive fungal infections in children aged 3–17 who are severely neutropenic after hematopoietic stem cell transplantation or similar high-risk conditions.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Haikou, Hainan · NCT07725263

• Anti-CD25 antibody to prevent acute GVHD after haploidentical stem cell transplant

  This study tests whether an anti-CD25 antibody can better prevent acute graft-versus-host disease after haploidentical hematopoietic stem cell transplantation compared with the usual methotrexate-based approach.

  Recruiting Phase 3 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07689630

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.